For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...

PhotoCure ASA (PHCUF) reports robust Q4 performance with significant revenue growth in the US and Europe, while navigating operational challenges and strategic opportunities.

At the end of the fourth quarter of 2024, the installed base of rigid blue light cystoscopy (BLC ®) systems in the U.S. was 390, up 11% since the same period in 2023. This includes 18 ForTec Medical ...

Photocure ASA ( ($PHCUF) ) has shared an announcement. Photocure ASA reported a strong financial performance for the fourth quarter of 2024, with ...

Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary ...

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

A urinary DNA methylation test demonstrated a high sensitivity for detecting high-grade or invasive bladder cancer, outperforming two other urine-based tests, a new study found.